myeloid
cell
often
overexpress
human
cancer
import
target
develop
antineoplast
drug
studi
data
set
contain
million
leadlik
molecul
data
set
us
food
drug
administr
fda
approv
drug
virtual
screen
potenti
ligand
use
protein
data
bank
pdb
id
potenti
ligand
evalu
comput
dock
three
conform
ensembl
gener
normal
mode
analysi
nma
molecular
dynam
md
nuclear
magnet
reson
nmr
respect
evalu
potenti
ligand
compar
clinic
use
remark
half
top
potenti
drug
use
clinic
treat
cancer
thu
partial
valid
virtual
screen
partial
valid
also
favor
idea
half
top
potenti
drug
could
use
treatment
cancer
normal
mode
md
nmrbase
conform
greatli
expand
conform
sampl
use
herein
silico
identif
potenti
inhibitor
apoptosi
highli
conserv
regul
process
elimin
damag
surplu
cell
gener
normal
embryon
develop
abnorm
cancer
import
regul
process
b
cell
lymphoma
famili
protein
includ
proand
antiapoptot
member
antiapoptot
ie
prosurviv
member
includ
bclxl
bclw
myeloid
cell
wherea
proapoptot
member
includ
baxlik
protein
bax
bak
bok
protein
bad
bim
bmf
bik
hrk
bid
puma
noxa
interact
proand
antiapoptot
protein
regul
key
element
cell
surviv
death
antiapoptot
protein
commonli
overexpress
number
human
cancer
foster
surviv
tumor
cell
inhibit
antiapoptosi
ie
promot
apoptosi
interfer
tumor
cell
surviv
sever
smallmolecul
drug
mimic
proapoptot
protein
develop
includ
oral
avail
deriv
bind
select
bclxl
bclw
interfer
cell
surviv
howev
bind
cancer
treat
compound
alon
complic
thing
upregul
key
factor
develop
resist
thu
unmet
need
design
ligand
particular
new
small
molecul
inhibit
major
cancer
target
overexpress
often
encount
human
cancer
overexpress
report
breast
cancer
lung
cancer
prostat
cancer
pancreat
cancer
cervic
ovarian
cancer
leukemia
overexpress
lead
resist
inhibitor
smallmolecul
drug
use
chemotherapi
remark
vitro
inhibit
overexpress
rna
silenc
inhibit
tumor
growth
abolish
chemoresist
repres
promis
cancer
target
virtual
screen
current
classic
tool
drug
discoveri
appli
search
novel
compound
target
given
protein
interest
comput
screen
approach
gain
gener
accept
comparison
highthroughput
screen
techniqu
abl
decreas
time
cost
limit
number
compound
must
experiment
test
two
main
approach
virtual
screen
ligandbas
structurebas
virtual
screen
latter
approach
often
use
threedimension
structur
drug
target
avail
experiment
studi
sever
experiment
structur
avail
list
supplementari
materi
tabl
assist
virtual
screen
sever
studi
use
molecular
dynam
md
simul
md
simul
wellestablish
method
understand
protein
dynam
case
md
simul
provid
snapshot
improv
virtual
screen
predict
power
known
crystal
structur
possibl
due
sampl
relev
conform
furthermor
unrestrain
md
simul
move
conform
previous
amen
dock
predict
rang
assist
virtual
screen
sever
studi
also
use
normal
mode
analysi
nma
nma
one
standard
techniqu
studi
longtim
dynam
particular
lowfrequ
motion
contrast
md
nma
provid
analyt
fulli
detail
descript
dynam
around
local
energi
minimum
conform
ensembl
gener
perturb
initi
structur
along
set
relev
lowfrequ
normal
mode
assist
virtual
screen
sever
studi
util
structur
ensembl
obtain
use
nuclear
magnet
reson
nmr
use
multipl
fix
conform
either
experiment
determin
crystallographi
nmr
practic
shortcut
may
improv
dock
calcul
sever
case
approach
led
experiment
valid
predict
thu
nmr
md
nma
use
separ
improv
virtual
screen
combin
three
assist
virtual
screen
inhibitor
studi
use
conform
sampl
three
separ
method
name
nma
md
simul
nmr
virtual
screen
novel
ligand
modul
activ
use
techniqu
two
curat
data
set
name
us
food
drug
administr
fda
approv
drug
leadlik
molecul
identifi
novel
small
molecul
could
detect
use
unperturb
protein
data
bank
pdb
structur
conform
sampl
use
model
nmr
structur
pdb
id
start
structur
usual
nmr
structur
consist
averag
structur
number
ensembl
structur
nmr
ensembl
structur
number
model
model
model
etc
averag
structur
avail
decid
use
model
pdb
id
start
structur
calcul
normal
mode
structur
pdb
id
model
two
program
util
name
stand
stand
real
normal
mode
rea
tirion
mode
tir
calcul
speed
stand
option
coars
grain
point
acceler
calcul
yet
flaw
result
use
default
valu
deform
amplitud
use
default
valu
dqmin
dqmax
util
dqmin
dqmax
paramet
correspond
deform
amplitud
direct
singl
normal
mode
stand
three
nontrivi
lowest
frequenc
mode
calcul
three
mode
six
pdb
model
gener
stand
six
model
structur
gener
fulli
distort
along
particular
mode
model
structur
subsequ
use
molecular
dock
run
unrestrain
md
structur
pdb
id
model
amber
simul
packag
simul
paramet
obtain
forc
field
protein
leaprcgaff
organ
molecul
sinc
use
water
ethanol
solvent
mixtur
md
simul
compris
three
stage
name
system
heat
use
constant
number
constant
volum
constant
virtual
screen
potenti
inhibitor
conform
temperatur
nvt
system
equilibr
use
constant
number
constant
pressur
constant
temperatur
npt
product
use
nvt
system
heat
use
nvt
ie
constant
volum
sinc
low
temperatur
pressur
calcul
may
lead
barostat
overcorrect
system
instabl
system
equilibr
use
npt
ie
constant
pressur
allow
system
densiti
equilibr
product
product
use
nvt
ie
constant
volum
md
simul
base
protocol
similar
one
describ
romerodurana
et
al
shortli
time
step
set
fs
heat
time
ps
equilibr
time
ns
product
time
ns
see
supplementari
materi
figur
obtain
hierarch
md
cluster
biomolecular
simul
trajectori
data
analysi
program
cpptraj
part
amber
packag
use
cluster
mean
partit
data
data
point
insid
cluster
similar
point
outsid
cluster
context
molecular
simul
mean
group
similar
conform
togeth
similar
determin
distanc
metric
smaller
distanc
similar
structur
one
commonli
use
distanc
metric
coordin
root
mean
squar
deviat
rmsd
applic
procedur
result
four
main
cluster
one
centroid
conform
pdb
structur
chosen
subsequ
molecular
dock
nmr
conform
ensembl
pdb
id
use
pdb
entri
contain
experiment
observ
structur
use
molecular
dock
identifi
potenti
inhibitor
two
molecular
data
set
virtual
screen
dock
use
autodock
vina
program
molecular
data
set
includ
leadlik
subset
fdaapprov
subset
leadlik
data
set
base
standard
leadlik
zinc
databas
version
septemb
contain
molecul
subset
molecul
randomli
select
leadlik
librari
prefilt
base
properti
molecular
weight
gmol
predict
partit
constant
logp
number
rotat
bond
fdaapprov
subset
contain
fdaand
intern
approv
drug
kindli
provid
dominiqu
douguet
institut
de
pharmacologi
et
cellulair
identifi
potenti
inhibitor
use
multipl
conform
protein
multipl
conform
compris
nmr
structur
conform
pdb
id
model
obtain
use
nma
four
model
obtain
use
md
simul
first
autodock
calcul
perform
repres
structur
nmr
ensembl
model
pdb
id
pick
ligand
lowest
bind
energi
dock
multipl
conform
sampl
nmr
nma
md
case
autodock
vina
linux
run
ahalama
cluster
equip
intel
processor
case
default
paramet
autodock
vina
follow
exhaust
global
search
maximum
number
bind
mode
gener
maximum
energi
differ
best
worst
bind
mode
display
kcalmol
ligand
best
pose
retain
case
bind
site
defin
limit
box
measur
x
z
coordin
center
dock
box
respect
box
encompass
entir
bind
groov
includ
bind
site
defin
belmar
fesik
combin
nmr
structur
nma
distort
model
md
simul
model
span
conform
space
md
model
rmsd
cover
larger
area
conform
space
nmr
nma
model
rmsd
valu
respect
nma
md
model
share
less
common
nmr
structur
deriv
contrast
md
nma
provid
detail
descript
dynam
around
local
energi
minimum
combin
conform
span
larger
area
conform
space
mani
pdb
structur
avail
list
supplementari
materi
tabl
molecular
dock
chose
pdb
id
structur
solv
without
peptid
ligand
believ
closest
nativ
state
protein
suffer
induc
fit
distort
test
valid
silico
assay
virtual
dock
sever
ligand
known
bind
compar
predict
bind
energi
experiment
bind
constant
ligand
includ
small
molecul
ligand
virtual
dock
multipl
conform
calcul
herein
use
autodock
vina
ligand
display
predict
attract
neg
bind
energi
follow
order
kcalmol
kcalmol
kcalmol
kcalmol
kcalmol
kcalmol
repuls
posit
bind
energi
kcalmol
remark
ligand
rank
accord
experiment
bind
constant
name
nm
nm
nm
nm
nm
nm
bind
small
molecul
bind
provid
posit
repuls
energi
assum
posit
bind
energi
error
pearson
correl
coeffici
predict
observ
bind
thu
small
data
set
predict
capac
silico
assay
confirm
set
test
larg
data
set
tabl
list
top
leadlik
molecul
see
supplementari
materi
figur
bind
conform
sampl
nmr
nma
md
top
leadlik
molecul
rank
accord
averag
bind
energi
interestingli
three
conform
nmr
nma
md
give
divers
top
rank
compound
top
ligand
lowest
averag
bind
energi
nmr
conform
ensembl
structur
relat
epinastin
structur
relat
famili
inhibitor
bind
nanomolar
affin
structur
relat
marinopyrrol
natur
product
isol
oblig
marin
streptomyc
bind
select
ic
induc
apoptosi
leukemia
melanoma
cell
structur
relat
acid
pdb
id
potent
inhibitor
kd
nm
virtual
screen
use
leadlik
molecul
provid
littl
inform
except
gener
skeleton
ligand
studi
leadlik
molecul
mostli
two
aromat
ring
link
hydrocarbon
chain
leadlik
molecul
often
display
nitrogen
hydrocarbon
chain
polycycl
aromat
ring
contrast
fdaapprov
drug
leadlik
molecul
littl
bioavail
pharmacodynam
activ
leadlik
molecul
also
risk
suffer
toxic
metabol
instabl
thu
inform
provid
leadlik
molecul
gener
skeleton
seem
common
inhibitor
date
virtual
dock
fdaapprov
drug
data
set
virtual
screen
potenti
inhibitor
conform
took
hour
nma
distort
model
took
hour
md
simul
model
hour
tabl
list
top
fdaapprov
drug
bind
conform
ensembl
sampl
nmr
nma
md
top
drug
rank
accord
averag
bind
energi
remark
eight
fdaapprov
drug
associ
cancer
treatment
could
becom
clinic
relev
top
ligand
lowest
averag
bind
energi
nmr
conform
ensembl
exemestan
levorphanol
cyproheptadin
dextromethorphan
epinastin
lenvatinib
sibutramin
oxcarbazepin
mirtazapin
darifenacin
figur
interestingli
two
exemestan
lenvatinib
clinic
use
approv
treatment
cancer
exemestan
thirdgener
aromatas
inhibitor
administ
breast
cancer
lenvatinib
vascular
endotheli
growth
factor
receptor
kinas
inhibitor
administ
thyroid
cancer
exemestan
lenvatinib
favor
candid
cancer
therapi
drug
among
top
ligand
includ
levorphanol
dextromethorphan
sibutramin
morphinelik
opioid
noradrenerg
serotonerg
activ
notabl
dextromethorphan
sometim
use
dull
pain
cancer
sever
clinic
trial
current
evalu
effect
peripher
neuropathi
manag
ie
clinicaltrialsgov
id
dextromethorphan
could
unexpect
effect
outcom
chemotherapi
treatment
mirtazapin
cyproheptadin
oxcarbazepin
epinastin
tricycl
compound
histaminerg
serotonerg
activ
use
control
pain
depress
antiemet
cancer
notabl
sever
clinic
trial
current
evalu
palli
cancer
manag
ie
clinicaltrialsgov
id
inde
activ
experiment
shown
drug
could
serv
adjuv
cancer
therapi
final
darifenacin
muscarin
agonist
use
urinari
incontin
littl
known
relationship
cancer
abbrevi
myeloid
cell
nmr
nuclear
magnet
reson
nma
normal
mode
analysi
md
molecular
dynam
figur
remark
four
associ
treatment
cancer
name
nilotinib
cabergolin
miltefosin
adapalen
nilotinib
select
bcrabl
tyrosin
kinas
inhibitor
approv
treatment
chronic
myelogen
leukemia
nilotinib
share
structur
similar
current
undergo
clinic
trial
combin
paclitaxel
treatment
relaps
solid
tumor
clinicaltrialsgov
id
nilotinib
promis
candid
cancer
therapi
cabergolin
ergot
deriv
potent
dopamin
receptor
agonist
use
treatment
prolactinoma
uterin
fibroid
cabergolin
contain
tricycl
ring
structur
relat
famili
inhibitor
famili
inhibitor
bind
nanomolar
affin
disrupt
complex
induc
baxbakdepend
apoptosi
increas
oxid
stress
disrupt
interact
beclin
cabergolin
current
undergo
clinic
trial
metastat
breast
cancer
adjuv
therapi
tamoxifen
clinicaltrialsgov
id
miltefosin
alkylphosphocholin
first
studi
treatment
cancer
approv
virtual
screen
potenti
inhibitor
conform
leishmaniasi
india
adapalen
thirdgener
topic
retinoid
inhibit
keratinocyt
differenti
prolifer
top
drug
four
atyp
antipsychot
name
ergotamin
paliperidon
lurasidon
risperidon
serotonerg
dopaminerg
activ
compos
tricycl
head
indolelik
tail
two
drug
seem
associ
cancer
dopamineserotonin
pharmacolog
deferasirox
oral
iron
chelat
use
reduc
chronic
iron
overload
eltrombopag
thrombopoietin
receptor
agonist
use
treatment
thrombocytopenia
top
ligand
lowest
averag
bind
energi
md
simul
conform
ensembl
azelastin
florbetapir
nebivolol
lenalidomid
dolasetron
droperidol
torsemid
mazindol
deferasirox
thalidomid
figur
remark
two
alreadi
associ
cancer
therapi
name
lenalidomid
thalidomid
induc
apoptosi
use
treatment
multipl
myeloma
myelodysplast
syndrom
thalidomid
lenalidomid
structur
analog
rhodanin
deriv
develop
degterev
et
al
bind
bind
groov
micromolar
affin
top
drug
least
three
dopaminerg
serotonerg
activ
dolasetron
serotonerg
dopaminerg
antagonist
use
nausea
droperidol
antidopaminerg
antipsychot
mazindol
catecholamin
reuptak
inhibitor
central
nervou
system
cn
stimul
trazodon
serotonerg
antagonist
reuptak
inhibitor
nebivolol
receptor
blocker
signific
dopaminerg
pharmacolog
structur
trazodon
particular
interest
rank
first
averag
final
three
drug
seem
link
serotonerg
dopaminerg
activ
azelastin
secondgener
histamin
receptor
antagonist
deferasirox
oral
iron
chelat
use
reduc
chronic
iron
overload
torsemid
pyridinesulfonylureatyp
loop
diuret
mainli
use
manag
edema
associ
supplementari
materi
tabl
bind
energi
ligand
standard
deviat
provid
standard
deviat
character
variat
averag
ligand
bind
energi
nmr
four
md
six
nma
conform
autodock
vina
appli
protein
conform
sampl
multipl
conform
signaltonois
ratio
true
posit
expect
increas
ligand
low
standard
deviat
bind
energi
usual
rotat
bond
rigid
sometim
symmetr
exampl
dihydroartemisinin
artemet
rigidifi
polycycl
skeleton
wherea
carbofenot
contain
axi
pseudosymmetri
contrarili
ligand
high
standard
deviat
highli
flexibl
standard
deviat
indic
entropi
conform
ligand
may
adopt
receptor
pose
possibl
often
drug
candid
low
standard
deviat
prefer
bind
confin
alway
remark
rank
order
fdaapprov
drug
compar
three
conform
ensembl
fdaapprov
drug
rank
high
nmr
ensembl
also
rank
high
md
nma
conform
drug
rank
low
nmr
ensembl
also
low
rank
md
nma
conform
figur
illustr
agreement
drug
rank
conform
sampl
nmr
nma
md
drug
rank
fdaapprov
drug
nmr
ensembl
md
conform
correl
well
pearson
correl
coeffici
drug
note
shown
scatter
plot
drug
rank
three
conform
famili
axi
enumer
drug
rank
nmr
nma
md
conform
respect
point
repres
one
fdaapprov
drug
color
accord
rank
top
rank
drug
color
red
bottom
rank
drug
color
blue
abbrevi
fda
food
drug
administr
nmr
nuclear
magnet
reson
nma
normal
mode
analysi
md
molecular
dynam
threedimension
rank
nmr
ensembl
nma
conform
correl
less
well
pearson
correl
coeffici
surprisingli
drug
rank
nma
conform
md
conform
correl
well
pearson
correl
coeffici
latter
correl
make
sens
light
diverg
path
nma
md
conform
origin
nmr
structur
studi
provid
compendium
potenti
inhibitor
potenti
inhibitor
identifi
virtual
screen
fdaapprov
drug
leadlik
molecul
multipl
conform
studi
base
silico
observ
claim
vitro
vivo
activ
studi
note
mani
potenti
inhibitor
current
undergo
clinic
trial
treatment
cancer
support
use
propos
complementari
mode
action
studi
recommend
clinic
trial
potenti
inhibitor
studi
bring
light
potenti
inhibitor
expos
scientif
commun
investig
studi
postul
addit
target
fdaapprov
drug
may
fact
also
act
drug
alreadi
undergo
clinic
trial
note
earlier
studi
pave
way
inform
clinic
trial
vivo
vitro
studi
experiment
bind
assay
importantli
drug
alreadi
approv
fda
treatment
cancer
clinic
use
potenti
inhibitor
could
promis
experi
know
dock
ligand
modul
target
structur
whether
act
agonist
antagonist
past
eg
inadvert
design
peptid
induc
prolifer
instead
apoptosi
unpublish
result
remain
unknown
potenti
inhibitor
propos
herein
act
agonist
antagonist
site
ligand
could
either
stabil
destabil
conform
requir
interact
apoptosi
experiment
data
vitro
vivo
clinic
trial
answer
question
autodock
vina
ligand
bind
energi
predict
kcalmol
importantli
howev
bind
energi
view
qualit
quantit
bind
indic
individu
valu
ligand
bind
energi
less
inform
bind
energi
rel
ligand
consider
kept
mind
analyz
valu
rel
valu
use
sinc
locat
insid
cytosol
potenti
drug
must
abl
cross
cell
membran
fdaapprov
drug
candid
list
form
membran
cross
report
leadlik
compound
howev
cellular
penetr
data
unavail
estim
base
predict
octanolwat
partit
coeffici
logp
avail
serotonerg
dopaminerg
histaminerg
hypothesi
serotonin
dopamin
histamin
regul
cell
prolifer
migrat
matur
apoptosi
varieti
cell
type
includ
lung
kidney
endotheli
cell
mast
cell
neuron
astrocyt
potenti
ligand
present
serotonerg
dopaminerg
histaminerg
modul
ie
ergotamin
paliperidon
lurasidon
risperidon
share
structur
similar
serotonin
dopamin
histamin
hypothes
serotonin
dopamin
histamin
modul
associ
coincid
support
viciou
cycl
depress
anxieti
cancer
character
abnorm
low
level
serotonin
dopamin
drug
design
develop
therapi
submit
manuscript
wwwdovepresscom
dovepress
dovepress
glantzgashai
et
al
